Aspira Pathlab & Diagnostics Current Liabilities
The Current Liabilities of Aspira Pathlab & Diagnostics (540788.BO) as of Oct 10, 2026 is 23.72 M INR. In the previous year, Current Liabilities was 20.71 M INR — a change of 14.55% (higher).
Get this data via API
Financial Data API
Current Liabilities
23.72 MINR
YoY
14.55%
Last updated:
The Aspira Pathlab & Diagnostics Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 23.72 MINR | +14.55% | |
| 20.71 MINR | +30.68% | |
| 15.85 MINR | -11.40% | |
| 17.89 MINR | -11.06% | |
| 20.11 MINR | -60.73% | |
| 51.21 MINR | +21.66% | |
| 42.10 MINR | +157.21% | |
| 16.37 MINR | -71.54% | |
| 57.51 MINR | +116.34% | |
| 26.58 MINR | +1,193.10% | |
| 2.06 MINR | — | |
| 0.00INR | — | |
| 0.00INR | — |
Aspira Pathlab & Diagnostics Stock analysis
Frequently Asked Questions about Aspira Pathlab & Diagnostics stock
Current Liabilities of Aspira Pathlab & Diagnostics is 23.72 M INR in 2025.
Current Liabilities of Aspira Pathlab & Diagnostics changed from 20.71 M INR to 23.72 M INR, representing a 14.55% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities Aspira Pathlab & Diagnostics since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Aspira Pathlab & Diagnostics historically and in real time.
Balance Sheet — Aspira Pathlab & Diagnostics
All Key Metrics — Aspira Pathlab & Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth